Evaluating efficacy of combination therapy with niosomal benzoyl peroxide and clindamyci

Phase 2

Recruiting

Conditions: acne vulgaris.
acne vulgaris

Registration Number: IRCT20170806035524N5

Lead Sponsor: Kerman University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

patients with age between 12 to 30 years old.
patients with mild to moderate acne vulgaris

Exclusion Criteria

pregnancy
lactation
history of allergy to clindamycin or BPO
previous history of inflammatory bowel disease,colitis
polycystic ovary syndrome,
hirsutism,
taking neuromuscular blockers or oral anti -acne drug since 6 months ago
topical anti-acne drugs since 1 month ago

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Acne lesion severity. Timepoint: At base line and 2,4, 8 and 12 weeks later. Method of measurement: Counting of acne lesions by physical examination, GAGS(Global Acne Grading System).;Number of counting of inflammatory and non-inflammatory acne lesions. Timepoint: At base line and 2,4, 8 and 12 weeks later. Method of measurement: counting of acne lesions by physical examination.;Quality of life. Timepoint: At base line and 2,4, 8 and 12 weeks later. Method of measurement: by Cardiff Acne Disability Index (CADI) questionnair.

Secondary Outcome Measures

Name	Time	Method
Erythema. Timepoint: at base-line(before intervention) and at weeks 2, 4, 8,12. Method of measurement: by physical examinatin.;Scaling. Timepoint: at base-line(before intervention) and at weeks 2, 4, 8,12. Method of measurement: by physical examination and classification of the severity of adverse effects to mild, moderate and severe.;Pruritis. Timepoint: at base-line(before intervention) and at weeks 2, 4, 8,12. Method of measurement: by physical examination and classification of the severity of adverse effects to mild, moderate and severe.